Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective

Jean-Louis Vincent¹ , Rolf Rossaint², Bruno Riou³, Yves Ozier⁴, David Zideman⁵ and Donat R Spahn⁶

¹Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, 1070 Brussels, Belgium

²Department of Anaesthesiology of the University Hospital, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany

³Department of Emergency Medicine and Surgery and Department of Anesthesiology and Critical Care, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, 47–83 Boulevard de l'Hôpital, 75651 Paris, France

⁴Service d'Anesthésie-Réanimation Chirurgicale, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, Faculté de Medecine, Paris-V, Université Rene-Descartes, 27 Rue du faubourg Saint-Jacques, 75679 Paris, France

⁵European Resuscitation Council, ERC Secretariat, Universiteitsplein 1, 2610 Antwerp, Belgium

⁶Department of Anaesthesiology, University Hospital Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland